CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 98 enrolled
Drug / intervention
Pioglitazone and Metformin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02099838
NCT02099838Phase 4Completed
CompareCT.gov

The Randomized Multiple Center Trial for The Effectiveness and Safety of Adding Compound Preparation of Pioglitazone and Metformin for Type 2 Diabetic Patients Who Have Bad Glycemic Control With the Initial Treatment of Sulfonylureas

Huazhong University of Science and Technology·interventional·Posted Mar 31, 2014·Updated Jun 25, 2014

In Brief

A Phase 4 clinical trial evaluating Pioglitazone and Metformin and Placebo for Diabetes Mellitus, Type 2. Completed, enrolled 98 participants across 1 site.

Detailed Summary

Secondary failure of sulfonylureas (SUs) can occur in about 30%-40% of type 2 diabetic patients after treatment with SUs for 5 years, although SUs are widely used in type 2 diabetic patients. This study was designed to evaluate the effectiveness and safety of adding compound preparation of pioglitazone and metformin for type 2 diabetic patients who have bad glycemic control with the initial treatment of SUs.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesChina
CollaboratorsWuhan Iron and Steel Workers' Hospital, Wuhan Pu-Ai Hospital, Hubei Xinhua Hospital

Timeline

Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMar 31, 2014
Enrollment StartJan 1, 2012
Primary CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 12.3 years ago

Interventions

Pioglitazone and Metformindrug

taking 1 tablet twice a day (before breakfast and before dinner) orally for 12 weeks

Placebodrug

taking 1 tablet twice a day (before breakfast and before dinner) orally for 12 weeks